PART I Overview We are a biopharmaceutical company that has developed ONS-5010/LYTENAVA TM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD. In June 2025, we launched directly into the initial markets of Germany and the UK. Additionally, our Bi...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-19 | 2025-09-30 | 0001104659-25-123264 | EDGAR | 98K words |
| 2024-12-27 | 2024-09-30 | 0001558370-24-016491 | EDGAR | — |
| 2023-12-22 | 2023-09-30 | 0001558370-23-020000 | EDGAR | — |
| 2022-12-29 | 2022-09-30 | 0001558370-22-019036 | EDGAR | — |
| 2021-12-23 | 2021-09-30 | 0001558370-21-017007 | EDGAR | — |
| 2020-12-23 | 2020-09-30 | 0001558370-20-014540 | EDGAR | — |
| 2019-12-19 | 2019-09-30 | 0001104659-19-074095 | EDGAR | — |
| 2018-12-18 | 2018-09-30 | 0001144204-18-065142 | EDGAR | — |
| 2017-12-29 | 2017-09-30 | 0001571049-17-008779 | EDGAR | — |
| 2016-12-29 | 2016-09-30 | 0001571049-16-020882 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001104659-26-016554 | EDGAR | 23K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011588 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001558370-25-007873 | EDGAR | — |
| 2025-02-14 | 2024-12-31 | 0001558370-25-001022 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012234 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008318 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0001558370-24-001172 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014866 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009942 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0001558370-23-001286 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013086 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001558370-22-008780 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-24 | 0001104659-26-086406 | EDGAR | — |
| 2026-07-24 | 0001104659-26-086685 | EDGAR | — |
| 2026-07-16 | 0001104659-26-084242 | EDGAR | — |
| 2026-03-25 | 0001104659-26-034601 | EDGAR | 21K words |
| 2026-03-16 | 0001104659-26-028103 | EDGAR | — |
| 2026-03-11 | 0001104659-26-026465 | EDGAR | — |
| 2026-03-10 | 0001104659-26-025893 | EDGAR | — |
| 2026-03-05 | 0001104659-26-024189 | EDGAR | — |
| 2026-02-18 | 0001104659-26-017118 | EDGAR | — |
| 2026-02-17 | 0001104659-26-015887 | EDGAR | — |
259 total filings indexed. 227 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001649989 |
| Ticker | OTLK |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.outlooktherapeutics.com |
| Listed | 2016-05-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/OTLK (~200 tokens, structured JSON with cryptographic provenance)